

## Voting Results from the General Meeting Held on January 18, 2019

**Daix (France), January 21<sup>st</sup>, 2019** – Inventiva S.A. (“Inventiva” or the “Company”), a biopharmaceutical company developing innovative therapies in nonalcoholic steatohepatitis (NASH), systemic sclerosis (SSc) and mucopolysaccharidosis (MPS), today announced, in accordance with the terms of Article R. 225-106-1 of the French “Code de commerce”, the voting results of its General Meeting held on January 18<sup>th</sup>, 2019.

The Company’s shareholders met during an Extraordinary and Ordinary General Meeting on January 18<sup>th</sup>, 2019 at the Hôtel Océania le Jura (Salon Pasteur – 14, avenue Foch, 21000 Dijon), following a notice of the meeting published in the “Bulletin des Annonces Légales Obligatoires” on December 28<sup>th</sup>, 2018 and by letters addressed to the registered shareholders.

The meeting was chaired by Mr. Frédéric Cren, Co-founder, Chief Executive Officer and Chairman of Inventiva.

Total number of shares: 22,276,977

Number of voting rights: 22,230,675

Number of shares held by shareholders present or represented by proxy or submitted by postal voting forms: 15,549,743

Number of voting rights held by shareholders present or represented: 9,978,681

Proportion of represented capital: 69.95%

	Shareholders	Voting Rights		Shares	Total number of voting rights
		Simple	Double		
<b>Present or proxies</b>	6	100 130	19 545 000	9 872 630	19 645 130
<b>Proxies to the President</b>	16	106 051		106 051	106 051
<b>Postal voting forms</b>	10	5 571 062		5 571 062	5 571 062
<b>TOTAL</b>	32	5 777 243	19 545 000	15 549 743	25 322 243

Resolution	Voting Results	Voted for		Voted against		Abstention	Off vote	Number of voting rights
		Number of voting rights	%	Number of voting rights	%	Number of voting rights		
<i>Resolution 1 – AGE</i>	<b>Adopted</b>	21 926 385	86.59%	3 395 858	13.41%	0		25 322 243
<i>Resolution 2 – AGE</i>	<b>Adopted</b>	21 926 385	86.59%	3 395 858	13.41%	0		25 322 243
<i>Resolution 3 – AGE</i>	<b>Adopted</b>	21 926 385	86.59%	3 395 858	13.41%	0		25 322 243
<i>Resolution 4 – AGE</i>	<b>Adopted</b>	21 926 385	86.59%	3 395 858	13.41%	0		25 322 243
<i>Resolution 5 – AGE</i>	<b>Adopted</b>	21 926 385	86.59%	3 395 858	13.41%	0		25 322 243
<i>Resolution 6 – AGE</i>	<b>Adopted</b>	21 926 385	86.59%	3 395 858	13.41%	0		25 322 243
<i>Resolution 7 – AGE</i>	<b>Adopted</b>	21 926 385	86.59%	3 395 858	13.41%	0		25 322 243
<i>Resolution 8 – AGE</i>	<b>Adopted</b>	21 926 385	86.59%	3 395 858	13.41%	0		25 322 243
<i>Resolution 9 – AGE</i>	<b>Adopted</b>	21 952 124	86.69%	3 370 119	13.31%	0		25 322 243
<i>Resolution 10 – AGE</i>	<b>Adopted</b>	21 926 385	86.59%	3 395 858	13.41%	0		25 322 243
<i>Resolution 11 – AGE</i>	<b>Adopted</b>	22 208 584	87.70%	3 113 659	12.30%	0		25 322 243
<i>Resolution 12 – AGO</i>	<b>Adopted</b>	22 317 839	88.14%	3 004 404	11.86%	0		25 322 243

**About Inventiva :** [www.inventivapharma.com](http://www.inventivapharma.com)

Inventiva is a biopharmaceutical company specialized in the development of product candidates interacting with nuclear receptors, transcription factors and epigenetic modulators. Inventiva’s research engine has the potential to open up novel therapies against fibrotic diseases, cancers and orphan diseases with substantial unmet medical needs.

Lanifibranor, its lead product, is an anti-fibrotic treatment acting on the alpha, gamma and delta PPARs (peroxisome proliferator-activated receptors), which play key roles in controlling the fibrotic process. Its anti-fibrotic action targets two initial indications with substantial unmet medical need: NASH, a severe and increasingly prevalent liver disease already affecting over 30 million people in the United States, and systemic sclerosis, a disease with a very high mortality rate and for which there is no approved treatment to date.

Inventiva is also developing a second clinical program with odiparcil for the treatment of patients with mucopolysaccharidosis type VI (or Maroteaux-Lamy syndrome), a rare and severe gene disease affecting children. Odiparcil has also the potential to address other MPS types, characterized by the accumulation of chondroitin or dermatan sulfate (MPS I or Hurler/Sheie syndrome, MPS II or Hunter syndrome, MPS IVa or Morquio syndrome and MPS VII or Sly syndrome). Inventiva is also developing a portfolio of early research projects in the field of oncology.

Inventiva benefits from partnerships with world-leading research entities, such as the Institut Curie in the field of oncology. Two strategic partnerships have also been established with world-class major pharmaceutical companies, AbbVie and Boehringer Ingelheim, in the fields of autoimmune diseases (specifically in psoriasis) and fibrosis, respectively. These partnerships provide milestone payments to Inventiva upon the achievement of pre-

clinical, clinical, regulatory and commercial milestones, in addition to royalties any approved products resulting from the partnerships.

Inventiva employs over 100 employees and owns R&D facilities near Dijon, acquired from the international pharmaceutical group Abbott. The Company owns, a proprietary chemical library of over 240,000 molecules as well as integrated biology, chemistry, ADME and pharmacology platforms.

### Contacts

#### **Inventiva**

Frédéric Cren  
President & CEO  
[info@inventivapharma.com](mailto:info@inventivapharma.com)  
+ 33 3 80 44 75 00

#### **Brunswick**

Julien Troisdorf / Yannick Tetzlaff  
Media relations  
[inventiva@brunswickgroup.com](mailto:inventiva@brunswickgroup.com)  
+ 33 1 53 96 83 83

#### **LifeSci Advisors**

Chris Maggos  
Investor relations  
[chris@lifesciadvisors.com](mailto:chris@lifesciadvisors.com)  
+ 41 79 367 6254